Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02218684
Recruitment Status : Completed
First Posted : August 18, 2014
Last Update Posted : August 18, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The trial objectives were to investigate the tolerability and pharmacokinetics of 80 mg telmisartan and 2, 4 or 6 mg lacidipine administered concurrently.

Condition or disease Intervention/treatment Phase
Healthy Drug: Telmisartan Drug: Lacidipine Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Tolerability and Pharmacokinetics of 80 mg Telmisartan in Combination With 2, 4, or 6 mg Lacidipine. An Open, Single Rising Dose Group Comparison Trial - Placebo Randomised Double Blind in Each Dose Group - in Male Healthy Subjects
Study Start Date : September 1998
Actual Primary Completion Date : November 1998

Resource links provided by the National Library of Medicine

Drug Information available for: Telmisartan

Arm Intervention/treatment
Experimental: Telmisartan + Lacidipine - low dose Drug: Telmisartan
Drug: Lacidipine
Experimental: Telmisartan + Lacidipine - medium dose Drug: Telmisartan
Drug: Lacidipine
Experimental: Telmisartan + Lacidipine - high dose Drug: Telmisartan
Drug: Lacidipine
Placebo Comparator: Placebo Drug: Placebo



Primary Outcome Measures :
  1. Cmax (Maximum measured concentration of the analyte in plasma) [ Time Frame: up to 72 hours after drug administration ]
  2. Number of subjects with adverse events [ Time Frame: up to 72 hours after drug administration ]

Secondary Outcome Measures :
  1. AUC (Area under the concentration-time curve of the analyte in plasma) [ Time Frame: up to 72 hours after drug administration ]
  2. tmax (Time from dosing to the maximum concentration of the analyte in plasma) [ Time Frame: up to 72 hours after drug administration ]
  3. CL/F (Apparent clearance of the analyte in plasma following extravascular administration) [ Time Frame: up to 72 hours after drug administration ]
  4. Vz/F (Apparent volume of distribution of the analyte during the terminal phase) [ Time Frame: up to 72 hours after drug administration ]
  5. MRT (Mean residence time of the analyte in the body) [ Time Frame: up to 72 hours after drug administration ]
  6. t½ (Terminal half-life of the analyte in plasma) [ Time Frame: up to 72 hours after drug administration ]
  7. Number of subjects with abnormal changes in laboratory parameters [ Time Frame: up to 72 hours after drug administration ]
  8. Number of subjects with clinically significant changes in vital signs [ Time Frame: up to 72 hours after drug administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male caucasian subjects as determined by results of screening
  • Written informed consent in accordance with Good Clinical Practice and local legislation given
  • Age >= 18 and <= 50 years
  • Broca >= -20% and <= + 20%

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate and Electrocardiogram (ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurologic disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (> 24 hours) (<= 1 month prior to administration or during the trial)
  • Use of any drugs which might influence the results of the trial (<= 10 days prior to administration or during the trial)
  • Participation in another trial with an investigational drug (<= 2 months prior to administration or during the trial)
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on study days
  • Alcohol abuse (> 60g/day)
  • Drug abuse
  • Blood donation > 100 ml (<= 4 weeks prior to administration or during the trial)
  • Excessive physical activities (<= 10 days prior to administration or during the trial)
  • Any laboratory value outside the reference range of clinical relevance
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02218684    
Other Study ID Numbers: 1173.1
First Posted: August 18, 2014    Key Record Dates
Last Update Posted: August 18, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Telmisartan
Lacidipine
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs